Literature DB >> 3802710

Cimetidine and ranitidine increase midazolam bioavailability.

J P Fee, P S Collier, P J Howard, J W Dundee.   

Abstract

Cimetidine has been shown to inhibit the oxidative metabolism of a variety of low- and high-extraction drugs. Despite the findings of initial investigators, there is evidence that ranitidine may exert similar effects. Eight healthy volunteer subjects took part in a within-subject crossover study. They received midazolam, 15 mg, by mouth after pretreatment with cimetidine, ranitidine, or nothing and midazolam, 10 mg, intravenously on separate occasions. Mean absolute bioavailability of midazolam was increased by more than 30% after cimetidine (P less than 0.01) and 26% after ranitidine (P less than 0.05). The data, which agree with a concurrent clinical study indicating greater hypnotic action of midazolam after ranitidine, indicate that this is not a result of enhanced midazolam absorption and that reduced hepatic clearance is the most likely explanation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3802710     DOI: 10.1038/clpt.1987.13

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

Review 1.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 2.  Pharmacology of drugs frequently used in ICUs: midazolam and flumazenil.

Authors:  R Amrein; W Hetzel
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Dose of midazolam should be reduced during diltiazem and verapamil treatments.

Authors:  J T Backman; K T Olkkola; K Aranko; J J Himberg; P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

Review 5.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

Review 6.  Pharmacokinetic drug interactions in anaesthetic practice.

Authors:  M Wood
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

7.  A pharmacokinetic interaction between roxithromycin and midazolam.

Authors:  J T Backman; K Aranko; J J Himberg; K T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 8.  Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

Authors:  Leah M Hesse; Lisa L von Moltke; David J Greenblatt
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

9.  General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.

Authors:  Yoshiyuki Ohno; Akihiro Hisaka; Hiroshi Suzuki
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  The effect of allopurinol on the steady-state pharmacokinetics of indomethacin.

Authors:  T Pullar; O Myall; J R Haigh; J R Lowe; J S Dixon; H A Bird
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.